Preimplantation Genetic Testing Market
Number of pages: 100 | Report Format: PDF | Published date: March 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 598.1 million |
|
Revenue Forecast in 2031 |
US$ 1,457.2 million |
|
CAGR |
10.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Technique, Application, End-user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global preimplantation genetic testing market was valued at US$ 598.1 million in 2022 and is expected to register a revenue CAGR of 10.4% to reach US$ 1,457.2 million by 2031.
Preimplantation Genetic Testing Market Fundamentals
Preimplantation genetic (PG) testing is the process of taking a cellular biopsy sample from a developing human oocyte or embryo obtained through an in vitro fertility (IVF) procedure, analyzing the genetic makeup of the sample, and using the results to select the best embryos for uterine transfer. Embryo implantation is one of the most pivotal stages in every IVF procedure. Transfer of a live embryo in a receptive endometrium is necessary for achieving pregnancy in an assisted reproduction cycle.
The primary challenge to overcome, especially when a single embryo transfer (SET) program is implemented for various clinical reasons, is the choice of the best embryo to transfer. The embryo selected for transfer in current practice is chosen based on morphologic grading criteria, which exhibits substantial variability. The number of cells, symmetry, and cellular fragments’ presence are assessed at the cleavage stage. The criteria assessed at the blastocyst stage include blastocyst expansion, inner cell mass, and trophectoderm appearance. There is a general agreement that an embryo’s viability and microscopic appearance are only weakly correlated. Thus, several non-invasive techniques were suggested to evaluate embryo quality, including proteomic and metabolomic studies and time-lapse imagery for embryo morpho-kinetics. Although extending embryo culture to the blastocyst stage has been demonstrated to improve SET results, morphologically normal blastocysts still carry a sizable chance of aneuploidy. Preimplantation genetic testing for aneuploidies (PGT-A) has become more significant due to the promising research showing that embryo aneuploidy is the primary cause of IVF failure. Aneuploidies in human embryos are closely correlated with the mother’s age and result from various chromosomal errors. Meiotic errors happen during oogenesis, and the meiotic apparatus degrades due to the protracted oocyte development halt in prophase. After fertilization, mitotic errors commonly occur during the first mitotic divisions, resulting in embryo mosaicism. When compared to oocyte aneuploidies, sperm aneuploidies are less frequent. However, their incidence in embryo aneuploidy is found to be significant. These aneuploidies are typically correlated with sperm quality and DNA fragmentation.
[68567]
Preimplantation Genetic Testing Market Dynamics
Growing awareness of diagnostic advancements, coupled with a significant number of neonatal deaths from complications during childbirth, is the main driver of the market’s expansion. Recent years have seen an increase in the prevalence of pediatric respiratory disorders, such as pneumonia and asthma, and congenital genetic diseases, such as Edwards syndrome. According to the WHO estimates of 2023, congenital diseases claim 240,000 newborns worldwide each year within the first 28 days of life. Nine out of ten children in low- and middle-income countries are born with a severe congenital disorder, and congenital disorders are responsible for an additional 170,000 deaths in children between the ages of 1 month and 5 years. These abnormalities are almost solely found in marriages between people with hereditary disorders, which are more common in developed countries. Therefore, the market for preimplantation genetic testing is driven by the rising demand for early diagnosis and advanced treatment solutions. Also, the market for preimplantation genetic testing is anticipated to grow significantly due to the advancement of medical knowledge and the development of technologically sophisticated genetic devices. The main opportunity is likely to be the favorable reaction from several regulatory bodies to genetic testing and potential chances for conceiving healthier children.
However, the primary factor impeding market development is public organizations’ ethical acceptability and judicial regulations that prevent the adoption rate of PG testing services. A few doctors and academics have also questioned the effectiveness of these procedures. Few people also recognize PG testing as immoral due to the deliberate unnatural creation and annihilation of the human embryo. This factor is also anticipated to limit market expansion. Nevertheless, genetics R&D is expected to present lucrative expansion prospects for market participants in preimplantation genetic testing.
Preimplantation Genetic Testing Market Ecosystem
The global preimplantation genetic testing market is analyzed from five perspectives: type, technique, application, end-user, and region.
Preimplantation Genetic Testing Market by Type
[546466]
Based on the type, the global preimplantation genetic testing market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis.
The preimplantation genetic diagnosis segment accounted for the largest revenue share of the global market in 2022. Preimplantation genetic diagnosis is used in conjunction with IVF to lessen the chance of passing on inherited conditions. Specific single-gene diseases (such as cystic fibrosis or sickle cell anemia) and chromosomal structural alterations in a parent are some of the most frequent causes of utilizing PG diagnosis. Families may also use it to have a child who can provide compatible stem cells for a family member who requires a bone marrow donor.
Preimplantation Genetic Testing Market by Technique
Based on the technique, the global preimplantation genetic testing market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, and single-nucleotide polymorphism.
The next-generation sequencing segment accounted for the largest revenue share of the global preimplantation genetic testing market in 2022. The primary benefit of next-generation sequencing is its ability to identify abnormalities throughout the complete genome, such as gene and exon copy number changes, chromosome inversions, and translocations. Next-generation sequencing has the advantage of identifying abnormalities with less DNA than traditional DNA sequencing methods can. Additionally, next-generation sequencing is less expensive and has a quicker turn-around time. Growing technological advancements in next-generation sequencing instruments and technologies are also anticipated to contribute to a sizable increase in market size. For instance, Harvard University, DNA Script, and Broad Institute received a US$ 23 million grant from the Intelligence Advanced Research Projects Activity in the U.S. in January 2020. The institutes are working together to develop cutting-edge technology incorporating NGS and enzymatic DNA synthesis into a single device. Many nations have invested in their national population genome mapping projects to better understand the relationship between genetics and disease. Government organizations are also sequencing millions of genomes to advance science and find better ways to diagnose and treat diseases such as cancer, rare disorders, and other afflictions. The adoption of next-generation sequencing technologies is likely to increase during the forecast period due to its few benefits, including cost efficiency, quick and accurate sample analysis, and technological advancements.
Preimplantation Genetic Testing Market by Application
Based on the application, the global preimplantation genetic testing market is segmented into aneuploidy, structural chromosomal abnormalities, single gene disorders, HLA typing, X-linked disorders, and gender identification. The structural chromosomal abnormalities segment is further sub-segmented into translocations, deletions, duplications, and inversions.
The aneuploidy segment accounted for the largest revenue share of the global preimplantation genetic testing market in 2022. Aneuploidy is an abnormal number of chromosomes, an extremely prevalent incidence in human gametes. Aneuploidy is, in fact, the most common genetic cause of spontaneous miscarriage and congenital disabilities in our species. The estimated prevalence of aneuploidy in human gametes and embryos differs greatly, with stillbirths having a 4% aneuploidy incidence, spontaneous miscarriages having a 35% aneuploidy incidence, and assisted fertility clinics having a 70% aneuploidy incidence. Due to the growing incidence of aneuploidy and the increasing maternal age, the aneuploidy segment accounts for the largest market revenue share.
The HLA typing segment is anticipated to expand significantly over the forecast period. This is due to the greater endurance rate of hematopoietic stem cell transplantation from linked paired donors compared to unrelated donors.
Preimplantation Genetic Testing Market by End-user
Based on the end-user, the global preimplantation genetic testing market is segmented into maternity centers & fertility clinics, hospitals & diagnostic labs, and research laboratories & academic institutes.
The maternity centers & fertility clinics segment accounted for the largest revenue share of the global preimplantation genetic testing market in 2022. The major drivers of this segment are the rising success rate of IVF technology, growing public awareness of IVF procedures, and the postponed onset of pregnancy. Worldwide demand for in vitro fertilization methods has been sparked due to rising success rates of IVF and growing awareness of advanced IVF techniques. In September 2021, the National Perinatal and Statistics Unit (Australia) showed that over the past ten years, IVF success rates have considerably increased and that the live birth rate per initiated IVF cycle in women using their eggs has increased by 18% overall, with even steeper improvements in older age groups. Up to 28% more live births will occur for every embryo transfer in 2020. Numerous factors, such as improvements in laboratory methods and the general treatment of infertility-affected couples, including changes in lifestyle, better diagnostic tools, and occasionally surgery performed before IVF, are responsible for the higher success rates.
Preimplantation Genetic Testing Market by Region
Based on the region, the global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global preimplantation genetic testing market in 2022. The increased prevalence of congenital disorders is the most important factor driving segment revenue growth. According to the 2022 statistics from the Centers for Disease Control and Prevention, one in every 33 infants (or about 3% of all babies) born in the United States annually has congenital disabilities. About 20% of all infant fatalities are caused by congenital disabilities, making them the main factor. Additionally, the preference for delaying pregnancy in women, their increasing support of technology to detect prenatal conditions, and the anticipated expense reductions brought on by economic growth are all expected to contribute significantly to developing the preimplantation genetic testing market in North America.
The market in Asia Pacific is also anticipated to experience significant development to account for the fastest revenue CAGR during the forecast period. The region has a growing healthcare sector and increasing disposable money. Large investments in big data and artificial intelligence technology by nations like China and Japan are also anticipated to continue being significant development drivers.
Preimplantation Genetic Testing Market Competitive Landscape
Many organizations emphasize introducing novel therapies, obtaining approval for those products, and engaging in other activities, such as awareness programs, as key development strategies. Furthermore, the market labeled partnerships, acquisitions, and various other types of collaboration as better growth strategies. Given the rising global demand for PG testing, these steps have increased the likelihood of future profitable growth prospects.
The notable participants in the global market are:
Preimplantation Genetic Testing Market Strategic Developments
Preimplantation genetic testing is a method of examining embryos created through in vitro fertilization for deficiencies before implantation.
Increased emergence of genetic disorders in newborns and emerging acceptance of in vitro fertilization are the important driving factors for the global preimplantation genetic market revenue growth.
The high cost of preimplantation genetic testing is the major restraining factor to the global market growth.
Key companies operating the global preimplantation genetic testing market are Agilent Technologies, Inc., Cegat GmbH, Illumina Inc., Invitae Corporation, and Laboratory Corporation of America Holdings.
The global preimplantation genetic testing market is expected to grow at a revenue CAGR of 10.4% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain